VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to- creatinine ratio (uPCR) by more than half in patients with immunoglobulin A (IgA) nephropathy, according to an interim analysis of the VISIONARY trial .

Beyond this clinical effect, a notable observation was the lack of safety concerns, especially given that, although sibeprenlimab is a selective agent, there may have been unexpected off-target effects.

“Safety's been a key consideration with these drugs,” study presenter Vlado Perkovic, MD, PhD, provost and scientia professor, University of New South Wales, Sydney, Australia, told Medscape Medical News .

Sibeprenlimab represents a new mechanism of action and “we don't yet fully understand the profile, so we've been looking at that data very c

See Full Page